Ambernath Revenue Contribution Delayed
Despite starting some revenue generation, Ambernath will only see full commercial impact in 2-3 years. Ambernath inventory has already added Rs 10-15 crore to working capital, pressuring cash conversion.
SUPRIYA / Q4-FY26 / risks
Keep the risk register visible.
Supriya Lifescience · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
EU GMP and USFDA Audit Scheduling Uncertainty
EU GMP audit for Ambernath pushed to H2 FY27 with no confirmed dates; USFDA audit dates yet to be scheduled due to auditor unavailability. Without EU approval, liquid anesthetic formulation ramp-up is delayed 3-4 years.
Gross Margin Pressure from New Product Scale-ups
Management deflected questions on gross margin deterioration, attributing some EBITDA margin pressure to Ambernath expenses without revenue offset. New cardiovascular and anesthetic products scale through semi-regulated markets initially.
Working Capital Intensity Rising
Inventory days running at ~200 days for 2 years; net working capital extended to 170-180 days due to Ambernath inventory buildup and higher intermediate stocks for scaled-up products.